Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1473 (LINC01473) is a long non-coding RNA (lncRNA), meaning it does not code for a protein product but functions at the RNA level. LINC01473 has been identified as differentially expressed in osteoblasts from patients with multiple myeloma compared to healthy controls, where its expression is upregulated. The biological role of LINC01473 remains largely uncharacterized, but preliminary research suggests it may be involved in regulating gene expression related to osteoblast activity and bone disease. Specifically, LINC01473 has shown co-expression with the mRNA of CD74—a gene implicated in immune response and bone remodeling—hinting at a potential regulatory function. Its altered expression may participate in the disrupted bone formation and immune evasion observed in multiple myeloma, but direct molecular mechanisms or validated therapeutic targeting have not yet been established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1473 (LINC01473).